VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscoelastic System.
Alcon Laboratories · Decision date Aug 4, 2026
What did the FDA approve?
FDA records P840064/S092 as a supplement to PMA P840064, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 4, 2026.
FDA approval order statement
An alternate manufacturing site at Alcon Fort Worth Manufacturing located at 6201 South Freeway, Fort Worth, Texas to perform the semiautomatic assembly of filled OVD (PROVISC, VISCOAT, and DUOVISC) syringes and components into blister packs, and packaging.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ophthalmic
- Decision date
- Aug 4, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P840064/S092
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Laboratories
- Product code
- LZP
- Decision code
- APPR
- Decision date
- Aug 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AID, SURGICAL, VISCOELASTIC.
- Applicant
- Alcon Laboratories
- Product code
- LZP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P840064. Subsequent supplements may change the device or its indications.
FDA decision timeline
P840064 · Original PMA
VISCOAT(TM)/DVOVISC/DISCOVISC OPHTHALMIC VISCOSURGICAL DEVICES
P840064/S090 · Related supplement
VISCOAT Ophthalmic Viscosurgical Device, DISCOVISC Ophthalmic Viscosurgical Device
P840064/S091 · Related supplement
VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscoelastic System; DISCOVISC Ophthalmic Viscosurgical D
P840064/S089 · Related supplement
VISCOAT Ophthalmic Viscosurgical Device
P840064/S092 received
Application receipt date recorded by FDA.
P840064/S092 · FDA decision
Normal 180 Day Track No User Fee
P840064/S094 · Related supplement
VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscosurgical System; DISCOVISC Ophthalmic Viscosurgical
Timeline entries are records held by MedtechLedger for P840064. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P840064
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories | PMA approval | Apr 30, 1986 | FDA | |
| Alcon Laboratories | PMA supplement | Jul 25, 2025 | FDA | |
| Alcon Laboratories | PMA supplement | Oct 3, 2025 | FDA | |
VISCOAT Ophthalmic Viscosurgical DeviceP840064/S089 | Alcon Laboratories | PMA supplement | Feb 10, 2026 | FDA |
| Alcon Laboratories | PMA supplement | Oct 1, 2026 | FDA |
Explore the linked device profile
Other records with product code LZP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S072 | Alcon Research, Ltd. | PMA supplement | Oct 1, 2026 | FDA |
Ophthalmic Viscosurgical Device FamilyP000046/S032 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S070 | Alcon Research, Ltd. | PMA supplement | Aug 4, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Jul 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Laboratories
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P840064/S092
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




